Emerging data suggest Retatrutide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may represent a significant advancement for body loss . Early human tests have shown considerable decreases in abdominal mass , possibly surpassing current obesity treatments. Despite this, further assessment is required to